Table 2.

VWF/FVIII concentrates licensed for the treatment of von Willebrand disease in Europe and North America

Product	Manufacturer	Purification	Viral inactivation	VWF:RCo/Ag# (Ratio)	VWF: RCo/FVIII# (Ratio)
Alphanate	Grifols	Heparin ligand chromatography	S/D + dry heat (80°C, 72 h)	0.47 ± 0.1	0.91 ± 0.2
Factor 8Y	BioProducts	Heparin/glycine precipitation	Dry heat (80°C, 72 h)	0.29	0.81
Fanhdi	Laboratory Grifols	Heparin ligand chromatography	S/D + dry heat (80°C, 72 h)	0.47 ± 0.1	1.04 ± 0.1
Haemate P/
Humate	CSL Behring	Multiple precipitation	Pasteurization (60°C, 10 h)	0.59 ± 0.1	2.45 ± 0.3
Talate	Shire	Ion exchange chromatography	S/D + vapor heat (60°C, 10 h)	0.47	1.1
Wilate	Octapharma	Ion exchange + size exclusion	S/D + dry heat (100°C, 2 h)	-	0.9
Wilfactin	LFB	Chromatography Ion Exchange + affinity	S/D, 35 nm filtration, dry Heat (80°C, 72 h)	≈0.95	≈50
VonVendi	Shire	Chinese Hamster Ovary (CHO) cell line co-expressing the VWF and FVIII genes, in absence of any animal or other human plasma proteins; purified by immune-affinity chromatography	-	-	-